Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Edwards Lifesciences

11/10/2021 | 06:34am EST


ę MT Newswires 2021
All news about EDWARDS LIFESCIENCES CORPORATION
06:28aINSIDER SELL : Edwards Lifesciences
MT
01/10INSIDER SELL : Edwards Lifesciences
MT
01/07Morgan Stanley Raises Price Target for Edwards Lifesciences to $148 From $144, Maintain..
MT
01/07Credit Suisse Lifts Edwards Lifesciences' PT to $144 from $131, Keeps Outperform Rating
MT
01/05Edwards lifesciences to present at the 40th annual j.p. morgan healthcare conference
PR
01/03Evercore ISI Adjusts Edwards Lifesciences PT to $130 From $128, Outperform Rating Kept
MT
2021Edwards Secures FDA Clearance for SAPIEN 3 Heart Valve With Alterra Prestent
MT
2021Edwards receives fda approval for sapien 3 with alterra prestent for transcatheter pulm..
PR
2021Edwards Lifesciences Corporation Receives FDA Approval for SAPIEN 3 with Alterra Preste..
CI
2021INSIDER SELL : Edwards Lifesciences
MT
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 5 256 M - -
Net income 2021 1 437 M - -
Net cash 2021 1 385 M - -
P/E ratio 2021 51,3x
Yield 2021 -
Capitalization 73 834 M 73 834 M -
EV / Sales 2021 13,8x
EV / Sales 2022 12,3x
Nbr of Employees 14 900
Free-Float 96,6%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 118,26 $
Average target price 130,81 $
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors